SGI
TVTX icon

Summit Global Investments’s Travere Therapeutics TVTX Stock Holding History

Summit Global Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-26,500
Closed -$761K – 307
2018
Q3 		$761K Buy
26,500
+2,600
+11% +$74.3K 0.1% 183
2018
Q2 		$652K Buy
+23,900
New +$636K 0.1% 194

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Summit Global Investments's TVTX Position: Q4 2018 in Review

Summit Global Investments sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 26,500 shares — an estimated $761K sold.

Summit Global Investments first reported a position in TVTX in Q2 2018 and held it in 2 quarters. The position peaked at $761K in Q3 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • Summit Global Investments reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Summit Global Investments sold 26,500 Travere Therapeutics shares in Q4 2018, an estimated $761K.
  • Summit Global Investments first reported a position in Travere Therapeutics in Q2 2018 and held it in 2 quarters.
  • Summit Global Investments's Travere Therapeutics position peaked at $761K in Q3 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on Summit Global Investments's 13F filing for Q4 2018, filed 8 Feb 2019.